NCT06829823View on ClinicalTrials.gov

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2029

Conditions

Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions

DRUG

N-803 and BCG

Combination therapy N-803 plus BCG

DRUG

N-803 and Gemcitabine

Combination therapy N-803 plus Gemcitabine

Sponsors

Lead Sponsor

ImmunityBio, Inc.

All Listed Sponsors

lead

ImmunityBio, Inc.

INDUSTRY